Diferencia entre revisiones de «Constipation»
(Prepared the page for translation) |
|||
| Línea 1: | Línea 1: | ||
''This page is for '''adult''' patients; for pediatric patients see [[constipation (peds)]].'' | <languages/> | ||
<translate> | |||
''This page is for '''adult''' patients; for pediatric patients see [[Special:MyLanguage/constipation (peds)|constipation (peds)]].'' | |||
==Background== | ==Background== | ||
[[File:Diameters of the large intestine.png|thumb|Normal inner diameters of colon sections.]] | [[File:Diameters of the large intestine.png|thumb|Normal inner diameters of colon sections.]] | ||
[[File:Rectum anatomy en.png|thumb|Anatomy of the anus and rectum.]] | [[File:Rectum anatomy en.png|thumb|Anatomy of the anus and rectum.]] | ||
*Acute constipation is intestinal obstruction until proven otherwise | *Acute constipation is intestinal obstruction until proven otherwise | ||
===Red flags=== | ===Red flags=== | ||
*Weight loss | *Weight loss | ||
*[[Rectal bleeding]]/melena | *[[Special:MyLanguage/Rectal bleeding|Rectal bleeding]]/melena | ||
*[[Nausea/vomiting]] | *[[Special:MyLanguage/Nausea/vomiting|Nausea/vomiting]] | ||
*[[Fever]] | *[[Special:MyLanguage/Fever|Fever]] | ||
*Rectal pain | *Rectal pain | ||
*Change in stool caliber | *Change in stool caliber | ||
==Clinical Features== | ==Clinical Features== | ||
[[File:BristolStoolChart.png|thumb|Bristol Stool Chart.]] | [[File:BristolStoolChart.png|thumb|Bristol Stool Chart.]] | ||
*Decreased frequency of bowel movements | *Decreased frequency of bowel movements | ||
*Hard, dry, and/or difficult to pass stool | *Hard, dry, and/or difficult to pass stool | ||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
</translate> | |||
{{Constipation DDX}} | {{Constipation DDX}} | ||
<translate> | |||
</translate> | |||
{{Anorectal DDX}} | {{Anorectal DDX}} | ||
<translate> | |||
</translate> | |||
{{DDX abdominal distention}} | {{DDX abdominal distention}} | ||
<translate> | |||
==Evaluation== | ==Evaluation== | ||
===Work up=== | ===Work up=== | ||
*Digital rectal exam | *Digital rectal exam | ||
*Abdominal panel | *Abdominal panel | ||
**CBC | **CBC | ||
**Chemistry ([[hypokalemia]] or [[hypercalcemia]]) | **Chemistry ([[Special:MyLanguage/hypokalemia|hypokalemia]] or [[Special:MyLanguage/hypercalcemia|hypercalcemia]]) | ||
**LFTs + lipase | **LFTs + lipase | ||
**Consider coagulation studies (PT, PTT, INR), as a marker of liver function | **Consider coagulation studies (PT, PTT, INR), as a marker of liver function | ||
*Consider [[TSH]] if concern for [[hypothyroid]] related [[constipation]] | *Consider [[Special:MyLanguage/TSH|TSH]] if concern for [[Special:MyLanguage/hypothyroid|hypothyroid]] related [[Special:MyLanguage/constipation|constipation]] | ||
*Consider [[lactate]] if concern for [[stercoral colitis]] | *Consider [[Special:MyLanguage/lactate|lactate]] if concern for [[Special:MyLanguage/stercoral colitis|stercoral colitis]] | ||
*CT if abdominal tenderness, elderly, or severe presentation | *CT if abdominal tenderness, elderly, or severe presentation | ||
**'''Constipation should not cause abdominal tenderness on exam''' | **'''Constipation should not cause abdominal tenderness on exam''' | ||
**CT may show stool burden in colon/rectum | **CT may show stool burden in colon/rectum | ||
===Diagnosis=== | ===Diagnosis=== | ||
*Diagnosis is frequently clinical | *Diagnosis is frequently clinical | ||
*In patients with concerning symptoms/risk factors, CT can confirm diagnosis and rule out more emergent conditions | *In patients with concerning symptoms/risk factors, CT can confirm diagnosis and rule out more emergent conditions | ||
==Management== | ==Management== | ||
*Adequate fluid (1.5L per day) | *Adequate fluid (1.5L per day) | ||
*Fiber (10gm per day) | *Fiber (10gm per day) | ||
**Bran: 1 cup daily | **Bran: 1 cup daily | ||
**[[Psyllium]] (Metamucil): 1-2 teaspoon TID | **[[Special:MyLanguage/Psyllium|Psyllium]] (Metamucil): 1-2 teaspoon TID | ||
*Exercise | *Exercise | ||
===Medication options=== | ===Medication options=== | ||
*Emollient | *Emollient | ||
**[[Docusate]] (Colace): 100mg QD-BID (facilitates mixture of stool fat and water) | **[[Special:MyLanguage/Docusate|Docusate]] (Colace): 100mg QD-BID (facilitates mixture of stool fat and water) | ||
**Mineral oil (long term use causes malabsorption) | **Mineral oil (long term use causes malabsorption) | ||
*Stimulants | *Stimulants | ||
**[[Bisacodyl]] (Dulcolax): 10mg PR TID | **[[Special:MyLanguage/Bisacodyl|Bisacodyl]] (Dulcolax): 10mg PR TID | ||
**[[Senna]]: Two tab PO QD-BID | **[[Special:MyLanguage/Senna|Senna]]: Two tab PO QD-BID | ||
*Saline laxative | *Saline laxative | ||
**Milk of mangesia: 15-30 mL QD-BID | **Milk of mangesia: 15-30 mL QD-BID | ||
**Magnesium citrate: 100-240 mL QD-BID | **Magnesium citrate: 100-240 mL QD-BID | ||
*Hyperosmolar agents | *Hyperosmolar agents | ||
**[[Lactulose]] 15-30 mL QD-BID | **[[Special:MyLanguage/Lactulose|Lactulose]] 15-30 mL QD-BID | ||
**[[Polyethylene glycol 3350|PEG]]: 1 gallon/4h | **[[Special:MyLanguage/Polyethylene glycol 3350|PEG]]: 1 gallon/4h | ||
**[[Polyethylene glycol 3350|PEG]](Miralax): 17gm | **[[Special:MyLanguage/Polyethylene glycol 3350|PEG]](Miralax): 17gm | ||
**Glycerin: 1 adult suppository PR, onset of action 15-30 min, then 1-2 doses per day | **Glycerin: 1 adult suppository PR, onset of action 15-30 min, then 1-2 doses per day | ||
*Enemas | *Enemas | ||
| Línea 68: | Línea 94: | ||
**Fleet Phospho-soda: 118 ml single enema dose, with maximum of x2 doses at least 1 hr apart | **Fleet Phospho-soda: 118 ml single enema dose, with maximum of x2 doses at least 1 hr apart | ||
***No more than 2 doses in a 24 hr period may be administered without serum phos, mag, calcium levels<ref>Farah R. Fatal acute sodium phosphate enemas intoxication. Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):392-3.</ref> | ***No more than 2 doses in a 24 hr period may be administered without serum phos, mag, calcium levels<ref>Farah R. Fatal acute sodium phosphate enemas intoxication. Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):392-3.</ref> | ||
***May observe [[hyperphosphatemia]], [[hypocalcemia]], [[hypomagnesemia]] | ***May observe [[Special:MyLanguage/hyperphosphatemia|hyperphosphatemia]], [[Special:MyLanguage/hypocalcemia|hypocalcemia]], [[Special:MyLanguage/hypomagnesemia|hypomagnesemia]] | ||
***High risk patients: renal impairement, abnormal gut motility, [[IBD]], elderly, cardiac co-morbidities<ref>Reedy JC, Zwiren GT. Enema-induced hypocalcemia and hyperphosphatemia leading to cardiac arrest during induction of anesthesia in an outpatient surgery center. Anesthesiology. 1983 Dec;59(6):578-9.</ref><ref>Korzets A, Dicker D, Chaimoff C, Zevin D. Life-threatening hyperphosphatemia and hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc. 1992 Jun;40(6):620-1.</ref> | ***High risk patients: renal impairement, abnormal gut motility, [[Special:MyLanguage/IBD|IBD]], elderly, cardiac co-morbidities<ref>Reedy JC, Zwiren GT. Enema-induced hypocalcemia and hyperphosphatemia leading to cardiac arrest during induction of anesthesia in an outpatient surgery center. Anesthesiology. 1983 Dec;59(6):578-9.</ref><ref>Korzets A, Dicker D, Chaimoff C, Zevin D. Life-threatening hyperphosphatemia and hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc. 1992 Jun;40(6):620-1.</ref> | ||
====Gastrografin PO==== | ====Gastrografin PO==== | ||
*Gastrografin through NG or OG decreases bowel wall edema and increases bowel motility<ref>Assalia A, Schein M, Kopelman D, et al. Therapeutic effect of oral Gastrografin in adhesive, partial small-bowel obstruction: A prospective randomized trial. Surgery 1994; 115: 433-437.</ref> | *Gastrografin through NG or OG decreases bowel wall edema and increases bowel motility<ref>Assalia A, Schein M, Kopelman D, et al. Therapeutic effect of oral Gastrografin in adhesive, partial small-bowel obstruction: A prospective randomized trial. Surgery 1994; 115: 433-437.</ref> | ||
**Diagnostic and therapeutic<ref>Chen SC, Lin FY, Lee PH, et al. Water-soluble contrast study predicts the need for early surgery in adhesive small bowel obstruction. Br J Surg 1998; 85: 1692-1694.</ref> | **Diagnostic and therapeutic<ref>Chen SC, Lin FY, Lee PH, et al. Water-soluble contrast study predicts the need for early surgery in adhesive small bowel obstruction. Br J Surg 1998; 85: 1692-1694.</ref> | ||
**100 cc of gastrografin through NG tube | **100 cc of gastrografin through NG tube | ||
**Transit may be observed through serial radiographs | **Transit may be observed through serial radiographs | ||
***Contrast within the large bowel within 24 hrs suggest partial [[small bowel obstruction]] | ***Contrast within the large bowel within 24 hrs suggest partial [[Special:MyLanguage/small bowel obstruction|small bowel obstruction]] | ||
***Contrast failing to reach large bowel within 24-48 hrs suggests complete obstruction, requiring laparotomy | ***Contrast failing to reach large bowel within 24-48 hrs suggests complete obstruction, requiring laparotomy | ||
**Therapeutic, may reduce necessary operative rate by ~75%<ref>Choi HK et al. Therapeutic Value of Gastrografin in Adhesive Small Bowel Obstruction After Unsuccessful Conservative Treatment: A Prospective Randomized Trial. Annals of Surgery. 2002;236(1).</ref> | **Therapeutic, may reduce necessary operative rate by ~75%<ref>Choi HK et al. Therapeutic Value of Gastrografin in Adhesive Small Bowel Obstruction After Unsuccessful Conservative Treatment: A Prospective Randomized Trial. Annals of Surgery. 2002;236(1).</ref> | ||
| Línea 82: | Línea 110: | ||
**Gastrografin is water-soluble and relatively safer if perforation occurs | **Gastrografin is water-soluble and relatively safer if perforation occurs | ||
**Be aware that anaphylactoid reactions and serious aspirations have occurred rarely with Gastrografin, however<ref>Skucas J. Anaphylactoid reactions with gastrointestinal contrast media. AJR Am J Roentgenol 1997; 168: 962-964.</ref> | **Be aware that anaphylactoid reactions and serious aspirations have occurred rarely with Gastrografin, however<ref>Skucas J. Anaphylactoid reactions with gastrointestinal contrast media. AJR Am J Roentgenol 1997; 168: 962-964.</ref> | ||
==Disposition== | ==Disposition== | ||
*Normally outpatient | *Normally outpatient | ||
==See Also== | ==See Also== | ||
*[[Constipation (peds)]] | |||
*[[Special:MyLanguage/Constipation (peds)|Constipation (peds)]] | |||
==References== | ==References== | ||
<references/> | <references/> | ||
[[Category:GI]] | [[Category:GI]] | ||
[[Category:Symptoms]] | [[Category:Symptoms]] | ||
</translate> | |||
Revisión actual - 21:57 4 ene 2026
This page is for adult patients; for pediatric patients see constipation (peds).
Background
- Acute constipation is intestinal obstruction until proven otherwise
Red flags
- Weight loss
- Rectal bleeding/melena
- Nausea/vomiting
- Fever
- Rectal pain
- Change in stool caliber
Clinical Features
- Decreased frequency of bowel movements
- Hard, dry, and/or difficult to pass stool
Differential Diagnosis
Constipation
- Behavioral-related
- Lack of exercise
- Diet-related
- Fecal impaction
- Ileus from surgical abdomen
- Bowel obstruction
- Small bowel obstruction
- Large bowel obstruction
- Malignant bowel obstruction
- Specific causes: tumor, stricture, hernia, adhesion, volvulus
- Painful anorectal disorders (e.g. anal fissure, hemorrhoids)
- Medical causes
- Hypothyroidism
- Electrolytes
- Hypokalemia
- Medication-related
- Opiods, antipsychotics, anticholinergics, antacid, antihistamines
- Constipation (peds)
Anorectal Disorders
- Anal fissure
- Anal fistula
- Anal malignancy
- Anal tags
- Anorectal abscess
- Coccydynia
- Colorectal malignancy
- Condyloma acuminata
- Constipation
- Crohn's disease
- Cryptitis
- GC/Chlamydia
- Fecal impaction
- Hemorrhoids
- Levator ani syndrome
- Pedunculated polyp
- Pilonidal cyst
- Proctalgia fugax
- Proctitis
- Pruritus ani
- Enterobius (pinworms)
- Rectal foreign body
- Rectal prolapse
- Syphilitic fissure
Non-GI Look-a-Likes
Abdominal distention
- Obesity
- Intestinal obstruction
- Pregnancy
- Ascites
- Cirrhosis
- Malignancy
- Heart failure
- Tuberculosis
- Spontaneous bacterial peritonitis
- Peritoneal dialysis-associated peritonitis
- Distended bladder / Acute urinary retention
- Constipation / fecal impaction
- Large tumor(s) (e.g. ovarian, lymphoma)
- Organomegaly
Evaluation
Work up
- Digital rectal exam
- Abdominal panel
- CBC
- Chemistry (hypokalemia or hypercalcemia)
- LFTs + lipase
- Consider coagulation studies (PT, PTT, INR), as a marker of liver function
- Consider TSH if concern for hypothyroid related constipation
- Consider lactate if concern for stercoral colitis
- CT if abdominal tenderness, elderly, or severe presentation
- Constipation should not cause abdominal tenderness on exam
- CT may show stool burden in colon/rectum
Diagnosis
- Diagnosis is frequently clinical
- In patients with concerning symptoms/risk factors, CT can confirm diagnosis and rule out more emergent conditions
Management
- Adequate fluid (1.5L per day)
- Fiber (10gm per day)
- Bran: 1 cup daily
- Psyllium (Metamucil): 1-2 teaspoon TID
- Exercise
Medication options
- Emollient
- Docusate (Colace): 100mg QD-BID (facilitates mixture of stool fat and water)
- Mineral oil (long term use causes malabsorption)
- Stimulants
- Saline laxative
- Milk of mangesia: 15-30 mL QD-BID
- Magnesium citrate: 100-240 mL QD-BID
- Hyperosmolar agents
- Enemas
- Soap suds, saline, tap water enema (rectal distention, causing evacuation)[1]
- May add 50-100 mg of docusate liquid to saline or water enema
- Fleet Phospho-soda: 118 ml single enema dose, with maximum of x2 doses at least 1 hr apart
- No more than 2 doses in a 24 hr period may be administered without serum phos, mag, calcium levels[2]
- May observe hyperphosphatemia, hypocalcemia, hypomagnesemia
- High risk patients: renal impairement, abnormal gut motility, IBD, elderly, cardiac co-morbidities[3][4]
Gastrografin PO
- Gastrografin through NG or OG decreases bowel wall edema and increases bowel motility[5]
- Diagnostic and therapeutic[6]
- 100 cc of gastrografin through NG tube
- Transit may be observed through serial radiographs
- Contrast within the large bowel within 24 hrs suggest partial small bowel obstruction
- Contrast failing to reach large bowel within 24-48 hrs suggests complete obstruction, requiring laparotomy
- Therapeutic, may reduce necessary operative rate by ~75%[7]
- Avoid barium as it becomes inspissated in bowel, causing complete obstruction[8]
- If perforation occurs with barium, leakage can be lethal
- Gastrografin is water-soluble and relatively safer if perforation occurs
- Be aware that anaphylactoid reactions and serious aspirations have occurred rarely with Gastrografin, however[9]
Disposition
- Normally outpatient
See Also
References
- ↑ Portalatin M and Winstead N. Medical Management of Constipation. Clin Colon Rectal Surg. 2012 Mar; 25(1): 12–19.
- ↑ Farah R. Fatal acute sodium phosphate enemas intoxication. Acta Gastroenterol Belg. 2005 Jul-Sep;68(3):392-3.
- ↑ Reedy JC, Zwiren GT. Enema-induced hypocalcemia and hyperphosphatemia leading to cardiac arrest during induction of anesthesia in an outpatient surgery center. Anesthesiology. 1983 Dec;59(6):578-9.
- ↑ Korzets A, Dicker D, Chaimoff C, Zevin D. Life-threatening hyperphosphatemia and hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc. 1992 Jun;40(6):620-1.
- ↑ Assalia A, Schein M, Kopelman D, et al. Therapeutic effect of oral Gastrografin in adhesive, partial small-bowel obstruction: A prospective randomized trial. Surgery 1994; 115: 433-437.
- ↑ Chen SC, Lin FY, Lee PH, et al. Water-soluble contrast study predicts the need for early surgery in adhesive small bowel obstruction. Br J Surg 1998; 85: 1692-1694.
- ↑ Choi HK et al. Therapeutic Value of Gastrografin in Adhesive Small Bowel Obstruction After Unsuccessful Conservative Treatment: A Prospective Randomized Trial. Annals of Surgery. 2002;236(1).
- ↑ Choi HK et al. Therapeutic Value of Gastrografin in Adhesive Small Bowel Obstruction After Unsuccessful Conservative Treatment: A Prospective Randomized Trial. Annals of Surgery. 2002;236(1).
- ↑ Skucas J. Anaphylactoid reactions with gastrointestinal contrast media. AJR Am J Roentgenol 1997; 168: 962-964.
